Q-linea AB (CHIX:QLINES) Risk Assessment


CHIX:QLINES Q-linea AB CHIX:QLINES
67 GF Score
Price kr1,610.00
GF Value kr1,921.76
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Q-linea AB is: No Data: Cannot be evaluated.

Q-linea AB  (CHIX:QLINEs) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Q-linea AB Risk Assessment Related Terms

CHIX:QLINES vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Q-linea AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q-linea AB Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Q-linea AB's Risk Assessment falls into.


CHIX:QLINES
67GF Score
Q-linea AB CHIX:QLINES
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr1,610.00 is trading 16.2% below its estimated GF Value™ of kr1,921.76.

Key valuation signals for CHIX:QLINES:

  • Risk Assessment:
  • GF Value™: kr1,921.76 vs. price of kr1,610.00 (16.2% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges QLINEA:Sweden3F80:Germany
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score

Get the complete analysis for CHIX:QLINES

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,610.00
Price
kr1,921.76
GF Value